

IAP15 Rec'd PCT/PTO 20 NOV 2005

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0951-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	Not Yet Assigned	
			Filing Date	Concurrently Herewith	
			First Named Inventor	Catherine Clelland	
			Art Unit	N/A 1637	
			Examiner Name	Not Yet Assigned Mark Staples	
Sheet	1	of	5	Attorney Docket Number	02420/100M850-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
MS/	AA*	US-5,578,832	11-26-1996	Trulson et al.	
	AB*	US-5,556,752	09-17-1996	Lockhart et al.	
	AC*	US-5,510,270	04-23-1996	Fodor et al.	
	AD*	US-5,539,083	07-23-1996	Cook et al.	
MS/	AE*	US-6,190,857	02-20-2001	Ralph et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number-Kind Code <sup>4</sup> (if known)			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
MS/	CA	Kim DK, <i>et al.</i> Neuropsychopharmacology 2001;25(1):84-90			
	CB	DeMattos RB, <i>et al.</i> Science 2002; 295:2264-2267			
	CC	Ilani <i>et al.</i> Proc Natl Acad Sci U S A 2001;98(2):625-8			
	CD	Cole <i>et al.</i> Nat Genet. 1999; 21(1 Suppl):38-41.			
	CE	Golub <i>et al.</i> Science 1999; 286(5439):531-7			
	CF	Alizadeh <i>et al.</i> Nature 2000; 403(6769):503-11			
	CG	Perou <i>et al.</i> Nature 2000; 406(6797):747-52			
	CH	Bittner <i>et al.</i> Nature 2000; 406(6795):536-40			
	CI	Dhanasekaran <i>et al.</i> Nature 2001; 412(6849):822-6			
	CJ	Luo <i>et al.</i> Mol Carcinog 2002; 33(1):25-35			
	CK	Nature 2002 ;415(6871):530-6			
	CL	Assersohn <i>et al.</i> Clin Cancer Res. 2002; 8(3):794-801			
	CM	Ensoli & Sirlanni, Crit Rev Oncog 1998; 9(2):107-24			
	CN	O Byrne & Dagleish, Br J Cancer 2001;85(4):473-83			
	CO	Kono <i>et al.</i> Clin Cancer Res. 1996; 2(11):1825-8			
	CP	Oliver and Nouri, Cancer Surv. 1992; 173-204			
	CQ	Lopez <i>et al.</i> Cell Immunol. 1998; 190(2):141-55			
	CR	Eisasser-Beile <i>et al.</i> J. Cancer Res Clin Oncol. 1993; 119(7):430-3			
	CS	Veltri <i>et al.</i> Urology 1999; 53(1):139-47			
	CT	Sirom <i>et al.</i> Prostate 2001; 1:47(4):269-75			
	CU	Nakashima <i>et al.</i> Cancer Res. 2000; 6(7):2702-6			
	CV	Fillella <i>et al.</i> Prostate 2000; 44(4):271-4			
	CW	De Vita <i>et al.</i> Oncol Rep. 2000; 7(2):357-61			
MS/	CX	O'Donovan <i>et al.</i> Am J Hum Genet 1999;65, 587-592			
Examiner Signature	/Mark Staples/ (10/20/2009)			Date Considered	10/20/2009

IAP15 Rec'd PCT/PTO 23 NOV 2005

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	Not Yet Assigned
--------------------	------------------

Filing Date	Concurrently Herewith
-------------	-----------------------

First Named Inventor	Catherine Clelland
----------------------	--------------------

Art Unit	N/A	1637
----------	-----	------

Examiner Name	Not Yet Assigned	Mark Staples
---------------	------------------	--------------

Attorney Docket Number	02420/100M850-US1
------------------------	-------------------

Sheet	2	of	5	Attorney
-------	---	----	---	----------

AM/	CY	Blackshaw <i>et al.</i> , Cell 2001;107:579-89	
	CZ	Oestreich <i>et al.</i> , Pharmacogenomics J. 2001; 1(4):272-87	
	CA1	Li <i>et al.</i> , Hum Mol Genet. 2004 13(6):609-16	
	CB1	Loring <i>et al.</i> , DNA Cell Biol. 2001;20:683-95	
	CC1	Saiki <i>et al.</i> , Science 1988, 239:487	
	CD1	Shuey <i>et al.</i> , Drug Discov Today. 2002 7(20):1040-6	
	CE1	Dorsett <i>et al.</i> , Nat Rev Drug Discov. 2004 3(4):318-29	
	CF1	Xu <i>et al.</i> , Biochem Biophys Res Commun. 2004 316(3):680-7	
	CG1	Devroe <i>et al.</i> , Expert Opin Biol Ther. 2004 4(3):319-27	
	CH1	Davidson <i>et al.</i> , Lancet Neurol. 2004 (3):145-9	
	CI1	Sambrook <i>et al.</i> , <i>supra</i> , 9.50-9.51	1989 see below
	CJ1	Sambrook <i>et al.</i> , <i>supra</i> , 11.7-11.8	
	CK1	Shalon <i>et al.</i> , Genome Research 1996, 639-645	for date
	CL1	Chee <i>et al.</i> , Science 1996, 274:610-614	
	CM1	Schena <i>et al.</i> , (Proc. Natl. Acad. Sci. USA; 1996, 93:10614	
	CN1	Shena <i>et al.</i> , Science 1995, 270:467-470	
	CO1	Froehner <i>et al.</i> , Nucleic Acid Res. 1986, 14:5399-5407	
	CP1	McBride <i>et al.</i> , Tetrahedron Lett. 1983, 24:245-248	
	CQ1	Egholm <i>et al.</i> , Nature 1993, 365:566-568	
	CR1	Nguyen <i>et al.</i> , Genomics 1995, 29:207-209	
	CS1	DeRisi <i>et al.</i> , Nature Genetics 1996, 14:457-460	
	CT1	Fodor <i>et al.</i> , Science 1991, 251:767-773	
	CU1	Pease <i>et al.</i> , Proc. Natl. Acad. Sci. USA 1994, 91:5022-5026	
	CV1	Lockhart <i>et al.</i> , Nature Biotech. 1996, 14:1675	
	CW1	Blanchard <i>et al.</i> , Biosensors & Bioelectronics 1996, 11:687-90	
	CX1	Moskows and Southern, Nuc. Acids Res. 1992, 20:1679-1684	
	CY1	Sambrook <i>et al.</i> , Molecular Cloning—A Laboratory Manual (2nd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989	
	CZ1	Chirgwin <i>et al.</i> , Biochemistry 1979, 18:5294-5299	
	CA2	Krug and Berger, Methods Enzymol. 1987, 152:316-325	
	CB2	Kricka, 1992, Nonisotopic DNA Probe Techniques, Academic Press San Diego, CA	
	CC2	Zhao <i>et al.</i> , Gene 1995, 156:207-213	
	CD2	Pietlu <i>et al.</i> , Genome Res. 1996, 6:492-503	
	CE2	Tijssen, 1993, Hybridization With Nucleic Acid Probes, Elsevier Science Publishers B.V	
	CF2	Ferguson <i>et al.</i> , Nature Biotech. 1996, 14:1681-1684	
	CG2	Slamon <i>et al.</i> , Science. 1987;9:235(4785):177-82	
	CH2	Willsher <i>et al.</i> , Breast Cancer Res Treat. 1996; 40(3):251-5	
	CI2	Draghici <i>et al.</i> , Drug Discov Today 2002; 7(11):555-563	
	CJ2	Akiyama, Schizophr Res 1999;37(1), 97-106	
	CK2	Kim, <i>et al.</i> , Biol Psychiatry 1998;43(9):701-4	
	CL2	Sperner-Unterwieser <i>et al.</i> , Schizophr Res 1999; 38(1):61-70	
	CM2	Muller <i>et al.</i> , Am J Psychiatry 1999;156(4):634-6	
	CN2	Cazzullo <i>et al.</i> , Schizophr Res 1998 31(1):49-55	
	CO2	Naudin <i>et al.</i> , Schizophr Res 1997 26(2-3):227-33	
	CP2	Greenlee <i>et al.</i> , CA Cancer J Clin. 2000; 50(1):7-33	
	CQ2	Oesterling <i>et al.</i> , JAMA 1993; 270(7):860-4	
	CR2	Seaman <i>et al.</i> , Urol Clin North Am.; 1993; 20(4):653-63	
	CS2	Catalona <i>et al.</i> , Urology 2000; 56(2):255-260	



Examiner  
Signature

/Mark Staples/ (10/20/2009)

Date	
Considered	

10/20/2009

APR 15 2009 23 NOV 2009

PTO/SB/08a/s (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	Not Yet Assigned
		Filing Date	Concurrently Herewith
		First Named Inventor	Catherine Clelland
		Art Unit	N/A 1637
		Examiner Name	Not Yet Assigned Mark Staples
		Attorney Docket Number	02420/100M850-US1
Sheet	3	of	5

MS/	CT2	Roberts <i>et al.</i> , Urology. 2000;56(5):817-22	
	CU2	Bangma <i>et al.</i> , J Urol. 1997;157(6):2191-6	
	CV2	Smith <i>et al.</i> , Cancer. 1997;80(9):1852-6	
	CW2	Neal <i>et al.</i> , Eur J Cancer 2000; 36(10):1316-21	
	CX2	Murphy <i>et al et al.</i> , Cancer. 1998;83(11):2259-69	
	CY2	Beckett <i>et al.</i> , Clin Cancer Res. 1999;5(12):4034-40	
	CZ2	Olsson CA. Urol Clin North Am. 1997;24(2):367-78	
	CA3	Lee <i>et al et al.</i> , Prostate 1999;39(3):213-8	
	CB3	Noguchi <i>et al.</i> , Int J Urol 1999;6:7-12	
	CC3	O'Dowd <i>et al.</i> , Urology. 2000;55(4):563-9	
	CD3	Amier <i>et al.</i> , Cancer Res. 2000; 60(21):6134-41	
	CE3	Cole <i>et al.</i> (Nat Genet. 1999; 21(1 Suppl):38-41	
	CF3	Schena <i>et al.</i> , Trends Biotechnol. 1999; 16(7):301-6	
	CG3	Yeang <i>et al.</i> , Bioinformatics. 2001;17 Suppl 1:S316-22	
	CH3	Thalmann <i>et al.</i> , Cancer Res. 1999; 54(10):2577-81	
	CI3	Chen <i>et al.</i> , J Cell Biol 2000; 151:1321-36	
	CJ3	Elmore <i>et al.</i> , N Engl J Med. 1998;338(16):1089-96	
	CK3	Berois <i>et al.</i> , Eur J Cancer 2000; 36(6):717-23	
	CL3	<i>et al.</i> , Int J Cancer. 1998;79(1):23-6	
	CM3	<i>et al.</i> , Proc Natl Acad Sci USA. 98(5):2646-51	
	CN3	Lopez-Otin & Diamandis Endocr Rev. ;19(4):365-96	
	CO3	Statist. Sinica. 2000; 12, 111-139	
	CP3	Yang <i>et al.</i> , Nat Rev Genet. 2002; 3(8):579-88	
	CQ3	Simon <i>et al.</i> , Genet Epidemiol. 2002; 23(1):21-36	
	CR3	Van t'Veer <i>et al.</i> , Nature 2002;415(6871):530-6	
	CS3	Spleiss <i>et al.</i> , Mol Psychiatry 1998; 3,512-20	
	CT3	Tsai <i>et al.</i> , J Affect Disord 2001; 64,185-93	
	CU3	Cloninger <i>et al.</i> , Am. J. Med. Genet. 1998; 81,275-281	
	CV3	Kinney <i>et al.</i> , J Affect Disord 1998; 50,117-24	
	CW3	Gunduz <i>et al.</i> , Schizophr Res. 1999; 40,237-433	
	CX3	Sortie <i>et al.</i> , Proc Natl Acad Sci U S A 2001; 98,10869-74	
	CY3	Colantuoni <i>et al.</i> , Neurobiol Dis. 2001; 8,847-65	
	CZ3	Mirnic <i>et al.</i> , Trends Neurosci. 2001; 24,479-86	
	CA4	Kwak <i>et al.</i> , BMC Med Genet. 2001; 2(1):3	
	CB4	Joyce <i>et al.</i> , Ann N Y Acad Sci. 1999; 877,595-613	
	CC4	Guillen <i>et al.</i> , Nature 2001; 411,86-9	
	CD4	Barbanti <i>et al.</i> , Mech Ageing Dev 2000; 120,65-75	
	CE4	Eur J Immunol. 2001; 31,3504-12	
	CF4	Nemanov <i>et al.</i> , Int J Neuropsychopharmacol. 1999; 2,25-29	
	CG4	Lin <i>et al.</i> , Schizophr Res. 1998; 32(1), 9-15	
	CH4	Ann Neurol. 2001; 50,699-707	
	CI4	Hakak <i>et al.</i> , Proc. Natl Acad Sci U.S.A. 2001; 98: 4746-51	
	CJ4	Ramaswamy <i>et al.</i> , Proc Natl Acad Sci U S A 2001;98(26):15149-54	
	CK4	Overall <i>et al.</i> , Psychol Rep. 1962; 10,799-812	
	CL4	Folstein J Psychiat Res. 1975, 12,189-198	
	CM4	Eisen <i>et al.</i> , Proc Natl Acad Sci. 1998; 95(25):14863-8	
	CN4	Muller <i>et al.</i> , Eur Arch Psychiatry Clin Neurosci 1997; 247: 308-13	
	CO4	Andreasen <i>et al.</i> , Br J Psychiatry 1989; Suppl (7), 49-58. 89)	
MS/	CP4	Andreasen <i>et al.</i> , Psychopathology 1995; 28: 7-17	

Examiner Signature	/Mark Staples/ (10/20/2009)	Date Considered	10/20/2009
--------------------	-----------------------------	-----------------	------------

PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	Not Yet Assigned
		Filing Date	Concurrently Herewith
		First Named Inventor	Catherine Clelland
		Art Unit	N/A 1637
		Examiner Name	Not Yet Assigned Mark Staples
Sheet	4	of	5
		Attorney Docket Number	02420/100M850-US1

/MS/	CQ4	Katzman <i>et al.</i> , (2001) In Iqbal, K., Sisdia, S.S., and Winblad, B. (eds), Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics. John Wiley and Sons, Ltd. Chichester, England, pp. 11-21	
	CR4	Ewbank <i>et al.</i> , Am J Public Health 1999; 89: 90-92	
	CS4	Tandon <i>et al.</i> , Genome Biol. Reviews 2002; 3: 3014.1-3014.9	
	CT4	Farrer <i>et al.</i> , JAMA 1997; 278: 1349-56	
	CU4	Galasko <i>et al.</i> , Arch Neurol 1994; 51: 888-95	
	CV4	Chui <i>et al.</i> , Neurology 1997; 49: 925-35	
	CW4	Bookheimer <i>et al.</i> , N Eng J Med 2000; 343: 450-6	
	CX4	Munzar <i>et al.</i> , Neurol Clin Neurophysiol 2002; 2002: 2-8	
	CY4	Mayeux <i>et al.</i> , Ann Neurol 1999; 46: 412-16	
	CZ4	Feldman <i>et al.</i> , J Alzheimers Dis 2001; 3: 507-516	
	CA5	Biochem Biophys Res Comm 2001; 284: 310-16	
	CB5	J Neurosci Res 2002; 70: 462-473	
	CC5	Neurology 2000; 54: 1297-1304	
	CD5	Armstrong <i>et al.</i> , Nat Genetics 2002; 30: 41-47	
	CE5	Lewis <i>et al.</i> , Am. J. Hum. Genet. 2003;73:34-48	
	CF5	Whittemore <i>et al.</i> , Am J Epidemiol. 1995, 141, 732-40	
	CG5	Easton <i>et al.</i> , The Prostate, 57: 261-269, 2003	
	CH5	Janer <i>et al.</i> , The Prostate, 57: 309-319, 2003	
	CI5	Brown <i>et al.</i> , Brit J. Cancer, 90: 510-514, 2004	
	CJ5	Witte <i>et al.</i> , The Prostate, 57: 298-308, 2003	
	CK5	Cunningham <i>et al.</i> , The Prostate, 57:335-346, 2003	
	CL5	Verhage <i>et al.</i> , Familial Cancer, 2: 57-67, 2003	
	CM5	Carpten <i>et al.</i> , Nat Genet, 30: 181-184, 2002	
	CN5	Tavtigian-SV., Nat Genet, 27:172-180, 2001	
	CO5	Gibbs <i>et al.</i> , Am J Hum Genet, 64: 776-787, 1999	
V/MS/	CP5	Abdul and Hoosein, Cancer Letters, 186: 99-105, 2002	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Mark Staples/ (10/20/2009)	Date Considered	10/20/2009
--------------------	-----------------------------	-----------------	------------